Document Detail

Survival time following hospital discharge in dogs with palliatively treated primary brain tumors.
MedLine Citation:
PMID:  23276095     Owner:  NLM     Status:  In-Data-Review    
Objective-To analyze survival time and identify prognostic factors associated with outcome following discharge in dogs with primary brain tumors treated palliatively. Design-Prospective case series. Animals-51 dogs with 5 histopathologic types of brain tumors. Procedures-Owners with dogs examined from 2004 to 2008 were invited to participate if dogs had CT or MRI evidence of a brain mass that was histopathologically confirmed as a neoplasm upon death, dogs survived for ≥ 48 hours after hospital discharge, and treatments following discharge were limited to administration of prednisone or phenobarbital. Prognostic factors, including signalment, clinical signs (including duration), tumor type, tumor location, degree of peritumoral edema, lesion burden, and prescribed treatment, were evaluated. Survival time was estimated and animal- and tumor-specific variables evaluated as potential prognostic factors. Results-The median survival time in all dogs was 69 days (95% confidence interval [CI], 18 to 201 days). Multivariate analyses identified neuroanatomic location as the only significant prognostic variable, with the survival time of dogs with infratentorial tumors (n = 18) being significantly shorter (median, 28 days; 95% CI, 19 to 68 days) than survival time of dogs with supratentorial (33) tumors (median, 178 days; 95% CI, 119 to 270 days). Seizures were the most common clinical sign associated with supratentorial tumors (24/33 [73%]) and central vestibular dysfunction with infratentorial tumors (12/18). Conclusions and Clinical Relevance-Dogs with palliatively treated primary brain tumors, particularly those with tumors in the cerebellum, pons, or medulla, had a poor prognosis. However, dogs with supratentorial tumors had survival times > 3 months.
John H Rossmeisl; Jeryl C Jones; Kurt L Zimmerman; John L Robertson
Related Documents :
23028705 - Gap junction enhancer increases efficacy of cisplatin to attenuate mammary tumor growth.
23646655 - Enhanced distribution and anti-tumor activity of ergosta-4,6,8(14),22-tetraen-3-one by ...
23280475 - Pattern analysis accounts for heterogeneity observed in mri studies of tumor angiogenesis.
22949155 - Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using ...
19016405 - Long-term caffeine consumption reverses tumor-induced suppression of the innate immune ...
18292535 - Tumor-specific cd4+ t cells render the tumor environment permissive for infiltration by...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of the American Veterinary Medical Association     Volume:  242     ISSN:  1943-569X     ISO Abbreviation:  J. Am. Vet. Med. Assoc.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7503067     Medline TA:  J Am Vet Med Assoc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  193-8     Citation Subset:  IM    
Department of Small Animal Clinical Sciences, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Current quality assurance concepts and considerations for quality control of in-clinic biochemistry ...
Next Document:  Effect of mepivacaine in an infraorbital nerve block on minimum alveolar concentration of isoflurane...